New discovery means diagnosis and support for people with rare gene anomaly | UniSC | University of the Sunshine Coast, Queensland, Australia

Accessibility links

Non-production environment - wwwtest.usc.edu.au

New discovery means diagnosis and support for people with rare gene anomaly

A global collaboration involving the Sunshine Coast Health Institute (SCHI) and the University of the Sunshine Coast (UniSC) has made a breakthrough discovery that could fast track diagnosis and support for families affected by a rare genetic disorder.

UniSC’s Professor Robert Harvey and Dr Lachlan De Hayr, who are based at the Sunshine Coast Health Institute, were part of a team of genomics researchers who found a new disorder associated with intellectual disability and heart malformations linked to alterations in the ZMYND8 gene (Zinc Finger MYND-Type Containing 8).

The findings were published in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics.

ZMYND8 was already known to have important functions in humans such as in DNA repair, transcription regulation and supressing tumours, but had not previously been linked to human cognition and learning.

Functional studies revealed that ZMYND8 variants abolish binding to other proteins involved in synapse formation and responses to DNA damage.

Professor Harvey said that people in Australia who are diagnosed with these ZMYND8 variants can now access disability funding through the National Disability Insurance Scheme (NDIS).

“In future, genetic testing for ZMYND8 gene variants will mean that other affected children and families can access a rapid diagnosis and appropriate support,” Professor Harvey said.

“This will help avoid a lengthy journey that often includes misdiagnosis, referrals to multiple specialists, invasive tests, and years of uncertainty.”

Functional studies were conducted by Professor Harvey and Dr De Hayr at the Sunshine Coast Health Institute, and Professor Annette Schenck at Radboud University Medical Centre and Associate Professor Irina Voineagu at UNSW Sydney.

The collaboration included Associate Professor Tony Roscioli from Neuroscience Research Australia, UNSW Sydney and New South Wales Health Pathology’s Randwick Genomics Laboratory and Dr Colleen Carlston at Boston Children’s Hospital and Harvard Medical School.

The study was largely funded through the Australian National Health and Medical Council’s support of the Centre for Research Excellence in Neurocognitive Disorders.

SCHI Operations Manager Clare Hanlon said researchers undertake targeted research in fields that will optimise treatments and health outcomes for people in our region.

“Our clinical research laboratories are used by researchers and clinicians from our partner organisations to investigate health-related conditions,” Ms Hanlon said.

“Some researchers, such as Professor Harvey, contribute to national and international collaborations.

“We also have academic researchers working with health clinicians to develop new patient models of care which are put into practice right here in our facilities on the Sunshine Coast.”

SCHI is a partnership between the Sunshine Coast Hospital and Health Service, the University of the Sunshine Coast, TAFE Queensland and Griffith University, with state-of-the-art teaching and research facilities located within the Sunshine Coast University Hospital.

Media enquiries: Please contact the Media Team media@usc.edu.au